JP2013537887A - ドライアイの治療用医薬組成物 - Google Patents

ドライアイの治療用医薬組成物 Download PDF

Info

Publication number
JP2013537887A
JP2013537887A JP2013527651A JP2013527651A JP2013537887A JP 2013537887 A JP2013537887 A JP 2013537887A JP 2013527651 A JP2013527651 A JP 2013527651A JP 2013527651 A JP2013527651 A JP 2013527651A JP 2013537887 A JP2013537887 A JP 2013537887A
Authority
JP
Japan
Prior art keywords
trpm8
methyl
ethyl
isopropyl
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013527651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013537887A5 (enExample
Inventor
ベルモンテ マルティネス カルロス
ガラー マルティネス ファナ
フェレール モンティエル アントニオ
フェルナンデス カルバハル エイジャ
ヴィアナ デ ラ イグレシア フェリックス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Científicas
Miguel Hernandez University
Original Assignee
Consejo Superior de Investigaciones Científicas
Miguel Hernandez University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Científicas, Miguel Hernandez University filed Critical Consejo Superior de Investigaciones Científicas
Publication of JP2013537887A publication Critical patent/JP2013537887A/ja
Publication of JP2013537887A5 publication Critical patent/JP2013537887A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2013527651A 2010-09-08 2011-09-08 ドライアイの治療用医薬組成物 Withdrawn JP2013537887A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP201031341 2010-09-08
ES201031341A ES2377785B2 (es) 2010-09-08 2010-09-08 Composición farmacéutica para el tratamiento del ojo seco.
PCT/ES2011/070627 WO2012032209A2 (es) 2010-09-08 2011-09-08 Composición farmacéutica para el tratamiento del ojo seco

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016190040A Division JP2017036298A (ja) 2010-09-08 2016-09-28 ドライアイの治療用医薬組成物

Publications (2)

Publication Number Publication Date
JP2013537887A true JP2013537887A (ja) 2013-10-07
JP2013537887A5 JP2013537887A5 (enExample) 2015-08-13

Family

ID=45811010

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2013527651A Withdrawn JP2013537887A (ja) 2010-09-08 2011-09-08 ドライアイの治療用医薬組成物
JP2016190040A Withdrawn JP2017036298A (ja) 2010-09-08 2016-09-28 ドライアイの治療用医薬組成物
JP2019094210A Pending JP2019131621A (ja) 2010-09-08 2019-05-20 ドライアイの治療用医薬組成物
JP2021068077A Ceased JP2021107422A (ja) 2010-09-08 2021-04-14 ドライアイの治療用医薬組成物
JP2024039617A Pending JP2024069452A (ja) 2010-09-08 2024-03-14 ドライアイの治療用医薬組成物
JP2025143562A Pending JP2025172101A (ja) 2010-09-08 2025-08-29 ドライアイの治療用医薬組成物

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2016190040A Withdrawn JP2017036298A (ja) 2010-09-08 2016-09-28 ドライアイの治療用医薬組成物
JP2019094210A Pending JP2019131621A (ja) 2010-09-08 2019-05-20 ドライアイの治療用医薬組成物
JP2021068077A Ceased JP2021107422A (ja) 2010-09-08 2021-04-14 ドライアイの治療用医薬組成物
JP2024039617A Pending JP2024069452A (ja) 2010-09-08 2024-03-14 ドライアイの治療用医薬組成物
JP2025143562A Pending JP2025172101A (ja) 2010-09-08 2025-08-29 ドライアイの治療用医薬組成物

Country Status (5)

Country Link
US (4) US9095609B2 (enExample)
EP (2) EP4268814A3 (enExample)
JP (6) JP2013537887A (enExample)
ES (1) ES2377785B2 (enExample)
WO (1) WO2012032209A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015108136A1 (ja) * 2014-01-17 2015-07-23 キッセイ薬品工業株式会社 α－置換グリシンアミド誘導体
JP2016535742A (ja) * 2013-10-22 2016-11-17 エドワード タク ウェイＷＥＩ， Ｅｄｗａｒｄ Ｔａｋ 感覚的不快感の治療向け局所薬としてのジ−イソプロピル−アルカン（ｄａｐａ）化合物
JP2018501194A (ja) * 2014-10-31 2018-01-18 アヴェント インコーポレイテッド 膀胱収縮の抑制に関連する用途のための方法および装置
JP2018158933A (ja) * 2018-06-06 2018-10-11 エドワード タク ウェイＷＥＩ， Ｅｄｗａｒｄ Ｔａｋ 感覚的不快感の治療向け局所薬としてのジ−イソプロピル−アルカン（ｄａｐａ）化合物
JP2023543727A (ja) * 2020-09-22 2023-10-18 フェルティン ファルマ アー／エス ニコチンの灼熱感の軽減のための経口アンタゴニスト組成物
JP2024509322A (ja) * 2021-04-29 2024-02-29 クーパーヴィジョン インターナショナル リミテッド Ｗｓ１２を放出するコンタクトレンズ

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2377785B2 (es) * 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento del ojo seco.
JP6110124B2 (ja) * 2012-04-18 2017-04-05 花王株式会社 運動神経活性化用皮膚塗布剤
CN103040976B (zh) * 2012-12-31 2014-01-15 刘建贞 一种促进面神经损伤外科吻合术后康复的药物
US12648955B2 (en) * 2013-10-22 2026-06-09 Iview Therapeutics, Inc. Method of treating ocular discomfort
US20150290029A1 (en) * 2014-04-11 2015-10-15 Edward Tak Wei Delivery Systems for Agents to treat Ocular Discomfort
JP7096152B2 (ja) * 2015-10-06 2022-07-05 オーラ・インコーポレーテッド 一過性受容体電位カチオンチャネルサブファミリーｍメンバー８（ｔｒｐｍ８）拮抗薬及び使用方法
EP3184524A1 (en) 2015-12-21 2017-06-28 Dompé farmaceutici S.p.A. 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as trpm8 antagonists
ES2625393A1 (es) * 2016-01-19 2017-07-19 Universidad Miguel Hernandez De Elche Compuestos agonistas del receptor trpm8 y sus aplicaciones
US11554104B2 (en) * 2017-08-18 2023-01-17 The Schepens Eye Research Institute, Inc. Compositions for the treatment of dry eye and methods of use thereof
US12303527B2 (en) 2018-04-18 2025-05-20 i.com medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
GB201807305D0 (en) * 2018-05-03 2018-06-20 Nicoventures Trading Ltd Vaporisable formulation
US12268706B2 (en) 2019-01-31 2025-04-08 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
EP3917510A4 (en) * 2019-02-01 2022-11-16 Marshall University Research Corporation POTENTIAL TRANSIENT RECEPTOR 8 (TRPM8) MELASTATIN ANTAGONISTS AND RELATED METHODS
WO2021195256A1 (en) * 2020-03-24 2021-09-30 Aerie Pharmaceuticals, Inc. Pharmaceutical preparation
WO2022105986A1 (de) * 2020-11-17 2022-05-27 Symrise Ag Neue kühlstoffe und zubereitungen, die diese enthalten
WO2022257981A1 (zh) * 2021-06-08 2022-12-15 广州岐微生物医药科技有限公司 化合物在抑制或杀灭螨虫及治疗干眼症中的应用
CA3242833A1 (en) * 2021-12-17 2023-06-22 Alcon Inc. OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND THEIR USES
US12601929B2 (en) 2022-04-28 2026-04-14 Coopervision International Limited Contact lens
CN118696254B (zh) * 2022-10-31 2026-01-13 库博光学国际有限公司 释放ws12的隐形眼镜
WO2024220876A1 (en) * 2023-04-19 2024-10-24 Alcon Inc. N-substituted c6 cyclyl carboxamide compounds and uses thereof
TWI910873B (zh) * 2023-10-27 2026-01-01 英商庫博光學國際有限公司 隱形眼鏡

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001122774A (ja) * 1999-10-22 2001-05-08 Lion Corp 眼科用組成物及びソフトコンタクトレンズへの吸着抑制方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57179121A (en) 1981-04-27 1982-11-04 Showa Kagaku Kogyo Kk Remedy for oculopathy
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
JPH1067684A (ja) * 1996-06-17 1998-03-10 Mitsubishi Chem Corp 涙液分泌促進剤
IL129138A0 (en) 1996-10-11 2000-02-17 Bristol Myers Squibb Co Methods and compositions for immunomodulation
CN1199617A (zh) 1996-12-18 1998-11-25 虎发光 一种治疗眼病的中成药
JPH10236972A (ja) * 1997-02-28 1998-09-08 Mitsubishi Chem Corp 涙液分泌促進剤
JP4591728B2 (ja) * 1998-12-28 2010-12-01 大正製薬株式会社 眼精疲労改善用点眼剤
US6569903B2 (en) * 1999-12-07 2003-05-27 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
AU2002364935A1 (en) 2001-10-09 2003-06-23 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
AU2003210663A1 (en) * 2002-01-25 2003-09-02 The Regents Of The University Of California Methods of modulating cold sensory perception
US20060084684A1 (en) * 2002-05-28 2006-04-20 Altana Pharma Ag Topically applicable pharmaceutical preparation
US6919348B2 (en) * 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
US20040109847A1 (en) 2002-07-15 2004-06-10 Lieping Chen Treatment and prophylaxis with 4-1BB-binding agents
JP2006500921A (ja) 2002-07-30 2006-01-12 ブリストル−マイヤーズ　スクイブ　カンパニー ヒト４−１ｂｂに対するヒト化抗体
IL152486A0 (en) * 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
DE10259619A1 (de) * 2002-12-18 2004-07-08 Metagen Pharmaceuticals Gmbh Verwendung einer TRPM8 aktivierenden Substanz zur Tumorbehandlung
JP4601265B2 (ja) * 2003-05-14 2010-12-22 ロート製薬株式会社 局所適用製剤
CA2530884C (en) * 2003-07-02 2016-01-12 Genentech, Inc. Trp-p8 active compounds and therapeutic treatment methods
CN1565501A (zh) 2003-07-08 2005-01-19 毛友昌 明目地黄新的制备工艺及其制剂
US20050137166A1 (en) * 2003-12-19 2005-06-23 Alcon, Inc. Use of cooling agents to relieve mild ocular irritation and enhance comfort
EP1802600A1 (en) 2004-10-13 2007-07-04 Bayer HealthCare AG Substituted 4-benzyloxy-phenylmethylamide derivatives as cold menthol receptor-1 (cmr-1) antagonits for the treatment of urological disorders
US20060111388A1 (en) * 2004-11-19 2006-05-25 University Of North Texas Health Science Center At Fort Worth Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
JP5078254B2 (ja) * 2004-12-17 2012-11-21 ロート製薬株式会社 眼科用組成物
WO2006088447A1 (en) 2005-02-15 2006-08-24 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof
GB0504194D0 (en) * 2005-03-02 2005-04-06 Givaudan Sa Organic compounds
WO2007017092A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 4-benzyloxy-benzoic acid amide derivatives
CN1775261A (zh) 2005-11-18 2006-05-24 北京阜康仁生物制药科技有限公司 明目地黄制剂及新的制备方法
CN1775263A (zh) 2005-11-18 2006-05-24 北京阜康仁生物制药科技有限公司 杞菊地黄制剂及新的制备方法
US7727516B2 (en) * 2006-02-28 2010-06-01 The Procter & Gamble Company Reduction of hair growth
RU2305517C1 (ru) 2006-03-09 2007-09-10 Сергей Васильевич Широков Способ лечения эпифоры
CN101405009B (zh) * 2006-03-23 2011-04-13 千寿制药株式会社 包含黄原胶和葡萄糖的眼科组合物
US7887859B2 (en) * 2006-11-02 2011-02-15 Riolan Technologies, Inc. Methods of treating epiphora
GB2451503B (en) * 2007-08-01 2011-10-12 Lrc Products Stimulating gel comprising a cyclic carboxamide coolant
CN101612199A (zh) 2008-06-28 2009-12-30 孙斌 治疗眼睛红肿和遇风流泪的冲洗液
FR2934778B1 (fr) * 2008-08-11 2012-09-28 Natura Cosmeticos Sa Compositions d'anti-transpirants et procedes permettant de reduire la transpiration chez les humains
US8653099B2 (en) * 2008-08-19 2014-02-18 Janssen Pharmaceutica Cold menthol receptor antagonists
ES2377785B2 (es) * 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento del ojo seco.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001122774A (ja) * 1999-10-22 2001-05-08 Lion Corp 眼科用組成物及びソフトコンタクトレンズへの吸着抑制方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL OF PHARMACOLOGY, vol. 141, JPN6015029565, 2004, pages 737 - 745, ISSN: 0003120936 *
CELL CALCIUM, vol. 41, JPN6015029562, 2007, pages 285 - 294, ISSN: 0003120935 *
CELL CALCIUM, vol. 42, JPN6015029571, 2007, pages 618 - 628, ISSN: 0003120934 *
IOVS, vol. 51, no. 8, JPN6015029568, August 2010 (2010-08-01), pages 3969 - 3976, ISSN: 0003120939 *
J PHARM PHARMACEUT SCI, vol. 13, no. 2, JPN6015029572, 22 July 2010 (2010-07-22), pages 242 - 253, ISSN: 0003120937 *
PROGRAM NO. 761.1. 2009 NEUROSCIENCE MEETINGPLANNER. CHICAGO, IL: SOCIETY FOR NEUROSCIENCE, 2009. ON, JPN6015029566, ISSN: 0003120938 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535742A (ja) * 2013-10-22 2016-11-17 エドワード タク ウェイＷＥＩ， Ｅｄｗａｒｄ Ｔａｋ 感覚的不快感の治療向け局所薬としてのジ−イソプロピル−アルカン（ｄａｐａ）化合物
WO2015108136A1 (ja) * 2014-01-17 2015-07-23 キッセイ薬品工業株式会社 α－置換グリシンアミド誘導体
JPWO2015108136A1 (ja) * 2014-01-17 2017-03-23 キッセイ薬品工業株式会社 α−置換グリシンアミド誘導体
JP2018501194A (ja) * 2014-10-31 2018-01-18 アヴェント インコーポレイテッド 膀胱収縮の抑制に関連する用途のための方法および装置
JP2018158933A (ja) * 2018-06-06 2018-10-11 エドワード タク ウェイＷＥＩ， Ｅｄｗａｒｄ Ｔａｋ 感覚的不快感の治療向け局所薬としてのジ−イソプロピル−アルカン（ｄａｐａ）化合物
JP2023543727A (ja) * 2020-09-22 2023-10-18 フェルティン ファルマ アー／エス ニコチンの灼熱感の軽減のための経口アンタゴニスト組成物
JP7860965B2 (ja) 2020-09-22 2026-05-18 フェルティン ファルマ アー／エス ニコチンの灼熱感の軽減のための経口アンタゴニスト組成物
JP2024509322A (ja) * 2021-04-29 2024-02-29 クーパーヴィジョン インターナショナル リミテッド Ｗｓ１２を放出するコンタクトレンズ
JP7777600B2 (ja) 2021-04-29 2025-11-28 クーパーヴィジョン インターナショナル リミテッド Ｗｓ１２を放出するコンタクトレンズ

Also Published As

Publication number Publication date
JP2017036298A (ja) 2017-02-16
US20170049728A1 (en) 2017-02-23
ES2377785A1 (es) 2012-04-02
JP2025172101A (ja) 2025-11-20
JP2019131621A (ja) 2019-08-08
US9901549B2 (en) 2018-02-27
US20130245231A1 (en) 2013-09-19
US20150313854A1 (en) 2015-11-05
EP4268814A2 (en) 2023-11-01
JP2021107422A (ja) 2021-07-29
JP2024069452A (ja) 2024-05-21
US10028920B2 (en) 2018-07-24
US20170071875A1 (en) 2017-03-16
US9433679B2 (en) 2016-09-06
EP2614860A4 (en) 2014-01-29
EP2614860A2 (en) 2013-07-17
ES2377785B2 (es) 2012-09-26
WO2012032209A2 (es) 2012-03-15
US9095609B2 (en) 2015-08-04
EP4268814A3 (en) 2024-01-24
WO2012032209A3 (es) 2012-07-12

Similar Documents

Publication Publication Date Title
JP2019131621A (ja) ドライアイの治療用医薬組成物
JP7416700B2 (ja) 増殖性硝子体網膜症および上皮間葉転換と関連付けられる状態の治療のためのｒｕｎｘ１阻害の方法
WO2017075222A1 (en) Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
US20180110837A1 (en) Methods and assays relating to macrophage differentiation
US20230035892A1 (en) Methods and compositions for treating cancer
KR20240055038A (ko) 다발성 경화증 치료를 위한 lou064
RU2663100C2 (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
KR102120060B1 (ko) 눈 컨디션의 치료 및/또는 예방을 위한 조성물 및 방법에 있어서 siRNA 및 이의 용도
US10011837B2 (en) SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
US20120231015A1 (en) Fragile x mental retardation protein (fmrp), compositions, and methods related thereto
ES2408132B1 (es) Composición farmacéutica para el tratamiento de la epífora.
WO2006102333A2 (en) Ophthalmic use of agents which inhibit connective tissue growth factor binding and signalling via the trka/p75ntr receptor complex
US20200352950A1 (en) Novel method of treating dystonia
JP2017200928A (ja) ｓｉＲＮＡならびに眼の状態の処置および／または予防のための方法および組成物におけるその使用
HK1211983B (en) Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141015

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20150320

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160929

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180111